Hep C Development Dilemma: Big Money Now or Bigger Money Later?
Executive Summary
As Big Pharma finds itself searching for products in smaller, more specialist markets, biotechs must decide whether it is better to take a product to market alone and reap the rewards while dealing with the risks, or take the money and run. Such is the happy dilemma for biotechs developing new drugs for HCV, an exploding market blessed with quick development timeframes and early proof-of-concept potential.
You may also be interested in...
In HCV, Protease Race Heats Up with Combo Therapy Looming
Two Phase III hepatitis C protease inhibitors from Vertex and Schering are set to reshape treatment for a difficult disease and potentially capture a significant chunk of a large and growing market. But other new therapies and combination regimens aren't far behind.
In HCV, Protease Race Heats Up with Combo Therapy Looming
Two Phase III hepatitis C protease inhibitors from Vertex and Schering are set to reshape treatment for a difficult disease and potentially capture a significant chunk of a large and growing market. But other new therapies and combination regimens aren't far behind.
Pacific Horizon: Encouraging Mutations in the Venture Model
Pacific Horizon is an active venture investor, often owning large majority stakes in its portfolio companies. The venture capitalist has taken two different strategies with its majority-owned virology investments, Illumigen and Koronis, eschewing and embracing risk, respectively. Each firm, however, represents a potential game-changing opportunity, and illustrates PHV's back-to-basics venture philosophy: making novel-mechanism bets that are perceived as having both high scientific risks and long-term potential paybacks